NDSIB
CRL icon

North Dakota State Investment Board’s Charles River Laboratories CRL Stock Holding History

North Dakota State Investment Board’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
1,450
+24
+2% +$4.27K 0.01% 644
2026
Q1 		$246K Sell
1,426
-247
-15% -$45.8K 0.01% 669
2025
Q4 		$334K Buy
+1,673
New +$303K 0.01% 650

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

North Dakota State Investment Board's CRL Position: Q2 2026 in Review

North Dakota State Investment Board increased its Charles River Laboratories (CRL) stake by 1.7% in Q2 2026, buying an estimated $4.27K and bringing the position to 1,450 shares worth $329K. The position accounts for 0.01% of the portfolio, ranked #644.

North Dakota State Investment Board first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. The position peaked at $334K in Q4 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • North Dakota State Investment Board held 1,450 shares of Charles River Laboratories worth $329K as of Q2 2026.
  • North Dakota State Investment Board bought 24 Charles River Laboratories shares in Q2 2026, an estimated $4.27K.
  • Charles River Laboratories made up 0.01% of North Dakota State Investment Board's portfolio in Q2 2026, its #644 holding.
  • North Dakota State Investment Board first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
  • North Dakota State Investment Board's Charles River Laboratories position peaked at $334K in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on North Dakota State Investment Board's 13F filing for Q2 2026, filed 4 Aug 2026.